Nexalin Technology, Inc. ((Nasdaq: NXL) (“Nexalin” or the “Company”), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the closing of its ...
MUNICH, June 08, 2022 (GLOBE NEWSWIRE) -- neurocare group AG ("neurocare" or the "Company"), a leading innovator in personalized mental health and performance empowering clinicians to deliver best ...
TVM's investment will enable neurocare to execute on its international growth plans Dubai: TVM Capital Healthcare, a specialist healthcare private equity firm headquartered in Dubai and Singapore, ...
Leadership continuity positions neurocare for its next decade of global expansion, innovation, and patient impact. MUNICH, DE / ACCESS Newswire / August 13, 2025 / neurocare group AG ("neurocare" or ...
neurocare group AG, a best practice platform for mental health and performance, is pleased to announce the appointment of Kevin Reeder as Chief Financial Officer of the company, from January 1st 2025.
Patient Receives Depression Treatment Using neurocare’s Apollo TMS System A patient undergoing Transcranial Magnetic Stimulation (TMS) therapy for depression with neurocare’s Apollo TMS System in a ...
Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive ALL We conducted a randomized trial of NeuroCARE versus usual care in PMBT caregivers with ...
MUNICH, Aug. 23, 2022 (GLOBE NEWSWIRE) -- neurocare group AG ("neurocare" or the "Company"), a leading innovator in personalized mental health and performance empowering clinicians to deliver best ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results